Kane Biotech Inc.

Good day, and thank you for standing by. And welcome to Kean Biotech Quarter 1, 2021 results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. Thank you. I would now like to hand the conference over to Mr. Ray Dupuy, Kane Chief Financial Officer. Sir, please go ahead.

Thank you, operator. Good afternoon and welcome everyone to Kane Biotech's quarterly conference call to discuss the company's financial results for Q1 2021. We are delighted to have you join us today. This call will cover Kane Biotech's financial and operating results for the first quarter ended March 31st, 2021. Kane Biotech's CEO, Mark Edwards, will begin by providing an overview of the quarter. I will then elaborate on the financial performance of the company in the quarter. Following our prepared remarks, we will open the conference call to question and answer session. But before we begin the presentation, let me caution you that our comments and discussions will include forward-looking information within the meaning of applicable securities legislation. Forward-looking information will include, among other things, forecasts and projections which involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from such forecasts and projections. Therefore, although we believe that anticipated future results, performance, or achievements expressed or implied by the forward-looking information are based on reasonable assumptions and expectations, you should not place undue reliance on such forward-looking information. Thank you, and I will now hand the call over to Mark Edwards, CEO of Kane Biotech.

Thank you, Ray, and welcome everyone listening in on today's call. Bonjour à vous tous. Kane has two proprietary technologies, CoactivePlus and DispersinB, that both prevent and disperse microbial biofilms, which are a big problem in multiple markets. What is a biofilm? Put simply, biofilm is is a community of microorganisms irreversibly attached to a surface. Think dental plaque, for example. Kane has identified three multi-billion dollar markets where biofilms are causing big problems and where we feel our technologies provide Kane the ability to win and grow. Throughout Q1, we continued to successfully execute our commercialization plan and made significant progress in all three verticals. With that, I'll hand it over to Ray Dupuy, our CFO, to go over the high-level financials, and I'll be back to share more exciting news about this progress.